RealFeedApp Seven therapies approved for blood cancers
While CAR T-cell therapies approved by the Alliance for Cancer Gene Therapy include Kymriah and Yescarta for blood cancers, they struggle with solid tumors and side effects like CRS and ICANS. Complex manufacturing and high costs limit the number of patients who can receive treatment.
- Field
- cancer research
- What they did
- Researchers are exploring alternative methods to activate the immune system, such as BiTE technology and the use of NK cells, to overcome the limitations of CAR T-cell therapy, which struggles with solid tumors and has high side effects.
- Why it matters
- This could help increase the number of patients who can receive treatment, as current methods are limited by complex manufacturing, high costs, and inefficacy against solid tumors.
#car t-cell therapy#solid tumors#immunotherapy#cytokine release syndrome#icans
